Share Email Print

Proceedings Paper

Imiquimod immunotherapy and ALA photodynamic therapy combination for the treatment of genital bowenoid papulosis
Author(s): Xiu-Li Wang; Hong-Wei Wang; Ming-Xia Guo; Zheng Huang
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

To investigate the feasibility and efficacy of combination of imiquimod immunotherapy and 5- aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for the treatment of genital bowenoid papulosis (BP). A total of twenty seven BP patients were randomized into two groups: (I) fifteen patients (12 male and 3 female, age 22-56 years old) were treated with topical application of 5% imiquimod cream (three times a week) and ALA-PDT (100 J/cm2 at 100 mW/cm2, once a week) for 1-4 times in one week interval. (II) Twelve patients (6 male and 6 female, age 29-58 years old) were treated with CO2 laser vaporization as a control. Patients were followed up for 3 to 12 months. Results: In combined therapy group, 60% (9/15) patients showed complete remission and only one recurred (11.1%) during follow up. Local side effects included mild erythema, edema, erosion and burning and/or stinging sensation. No systemic side effect was found. In CO2 laser vaporization group, 83.3% (10/12) patients showed complete remission. However, recurrence occurred in 6 patients (60.0%). Local side effects included mild to moderate edema, erosion, ulceration, delayed healing, prolonged pain and scarring. The difference of recurrence rate between two groups was statistically significant (P < 0.05). Topical application of imiquimod cream and ALA-PDT is safe, effective and associated with low recurrence and less side effect. Its true clinical value needs to be further investigated by a long-term follow-up of large scale trial.

Paper Details

Date Published: 13 February 2007
PDF: 7 pages
Proc. SPIE 6438, Biophotonics and Immune Responses II, 643809 (13 February 2007); doi: 10.1117/12.698774
Show Author Affiliations
Xiu-Li Wang, Shanghai Skin Diseases and STD Hospital (China)
Hong-Wei Wang, Shanghai Skin Diseases and STD Hospital (China)
Ming-Xia Guo, Shanghai Skin Diseases and STD Hospital (China)
Zheng Huang, Univ. of Colorado at Denver and Health Sciences Ctr. (United States)

Published in SPIE Proceedings Vol. 6438:
Biophotonics and Immune Responses II
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top